Ph 2 Elacestrant in ER Positive Uterine Sarcomas

This study is to evaluate the efficacy and safety of elacestrant, in participants with advanced estrogen receptor (ER)-positive uterine sarcomas. The name of the study drug involved in this research study is: -Elacestrant (a type of selective estrogen receptor degrader)

NCT Number	NCT07467772
Lead Sponsor	Dana-Farber Cancer Institute Collaborators: Stemline Therapeutics, Inc.
Conditions	Uterine Sarcoma, Uterine Leiomyosarcoma, Endometrial Stromal Sarcoma, ESS, Perivascular Epithelioid Cell Tumors, Uterine Adenosarcoma, Uterine PEComa, Estrogen Receptor Positive Tumor +1 more
Enrollment	30 participants
Start Date	2026-03-25
Primary Completion	2027-07 (estimated)
Study Completion	2028-04 (estimated)
Updated on ClinicalTrials.gov	2026-05-22